August 24, 2012
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science (CBIS) announced today the appointment of J. Thomas August, MD, Professor, Pharmacology and Molecular Sciences, and Oncology, The Johns Hopkins School of Medicine, to the Company’s Scientific Advisory Board.
Dr. August’s distinguished career in clinical research directed at the molecular biology and protein structure of RNA viruses, and clinical exploration of human immunology has positioned him as a leading authority on human immune response mechanisms.
“I am excited to have the opportunity to be involved in developing CS-TATI-1 to address the global incidence of Karposi’s Sarcoma being caused by HIV. Karposi’s Sarcoma is now the leading cancer in Africa, costing the lives of millions of people each year,” said Dr. August.
Dr. August currently holds the positions of a University Distinguished Service Professor of Pharmacology and Molecular Sciences, and Oncology at The Johns Hopkins University School of Medicine, Professor of Medicine, National University of Singapore; and Professor, Perdana University Graduate School of Medicine, Malaysia.
Dr. August has been involved with the development of a new generation of HIV vaccines and the protein antigenic structure of leading viral pathogens, including HIV-1, influenza, and other pathogens including dengue and West Nile viruses. His numerous publications are reflective of scientific commercial enterprises in cancer and HIV.
“We are honored to have Dr. August join our growing Scientific Advisory Board and consider his appointment to be another hallmark in our company’s efforts to bring CS-TATI-1 closer to further clinical investigation,” said Dr. Robert Melamede, President and CEO of Cannabis Science.
Cannabis Science continues to build a team of leading experts in clinical and basic science to further facilitate the company’s hallmark CS-TATI-1 research and development program and other early stage product development programs focusing on medicinal applications for phytocannabinoid-based research.
“There are currently no affordable treatments that can be brought from scale of economy to measure for developing nations bearing the blunt of the global AIDS pandemic, which is causing Karposi’s Sarcoma. The production measures of CS-TATI-1 offers the promise of addressing this horrible disparity in unprecedented ways”, concludes Dr. Melamede.
Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
HIV’s ability to mutate and reproduce itself even in the presence of antiretroviral drugs has led to a growing rate of drug resistance. Increasing drug resistance is severely limiting treatment options for HIV patients around the world, increasing direct and indirect health costs, furthering the spread of drug resistant strains of HIV and creating a pressing need to develop new HIV drugs.
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the transdermal delivery of CS-TATI-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Recent presentations at AIDS 2012 and The International Conference on Antiviral Research have provoked federal research interest in the development of CS-TATI-1.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Robert J. Melamede, 888-889-0888
President and CEO
Robert Kane, 561-234-6929
VP of Investor Relations